Physician profile
Allison K Weeks
NPI 1396045035
$7,194.22
in general payments reported to CMS, 2019-2025
52 companies · $1,519 in 2025
The $1,519 reported for 2025 was more than what 90% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $876 · 2022: $1,385 · 2023: $1,836 · 2024: $1,578 · 2025: $1,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,372 · Education: $561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,372.34 |
| Education | $560.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $748.15 | 2021-2025 | Erleada, Darzalex, Tecvayli |
| Seagen INC. | $661.54 | 2021-2025 | Adcetris, Padcev |
| Pfizer INC. | $548.41 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $446.11 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $427.55 | 2021-2025 | Calquence, Lynparza, Enhertu |
| Celgene Corporation | $359.92 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $262.83 | 2021-2025 | Ninlaro, Iclusig, Fruzaqla |
| Rigel Pharmaceuticals, INC. | $218.08 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Pharmacyclics LLC, An Abbvie Company | $214.41 | 2021-2023 | Imbruvica |
| Abbvie INC. | $207.42 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $198.26 | 2023-2025 | |
| Genentech USA, INC. | $175.97 | 2021-2025 | Tecentriq, Alecensa, Venclexta |
| Pharmaessentia USA Corporation | $172.39 | 2022-2025 | Besremi |
| Sobi, INC | $167.25 | 2022-2024 | |
| Mirati Therapeutics, INC. | $157.73 | 2023-2024 | Krazati |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $157.22 | 2021-2025 | |
| Eisai INC. | $150.22 | 2021-2025 | |
| Astellas Pharma US INC | $140.31 | 2023-2025 | Vyloy, Padcev, Xospata |
| Karyopharm Therapeutics INC. | $138.50 | 2021-2025 | Xpovio |
| Epizyme, INC. | $113.28 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $110.52 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $91.63 | 2021-2025 | |
| Lilly USA, LLC | $91.44 | 2021-2024 | Verzenio |
| Merck Sharp & Dohme LLC | $91.11 | 2023-2025 | Keytruda, Welireg |
| Gilead Sciences, INC. | $87.72 | 2023-2025 | Trodelvy |
| Janssen Pharmaceuticals, INC | $82.92 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $79.65 | 2024-2025 | Opdivo, Opdualag |
| Adc Therapeutics America, INC. | $70.85 | 2022-2025 | |
| Glaxosmithkline, LLC. | $70.59 | 2024-2025 | Ojjaara |
| Amgen INC. | $65.79 | 2021-2023 | Nplate, Vectibix, Xgeva |
| Incyte Corporation | $63.47 | 2021-2024 | Jakafi |
| Emd Serono, INC. | $60.97 | 2021-2024 | Bavencio |
| Blueprint Medicines Corporation | $50.79 | 2023 | Ayvakit |
| Exelixis INC. | $50.25 | 2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $45.35 | 2023-2024 | Libtayo |
| Aveo Pharmaceuticals, INC. | $42.70 | 2021-2023 | Fotivda |
| Pharmacosmos Therapeutics INC. | $32.09 | 2022 | |
| Stemline Therapeutics INC. | $31.52 | 2023 | Orserdu |
| Alexion Pharmaceuticals, INC. | $31.47 | 2021-2024 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $29.59 | 2022-2023 | Givlaari |
| Daiichi Sankyo INC. | $27.70 | 2021-2025 | Enhertu |
| Array Biopharma INC | $27.47 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Geron Corporation | $26.50 | 2025 | Rytelo |
| Sumitomo Pharma America, INC. | $24.18 | 2025 | Orgovyx |
| Beone Medicines USA, INC. | $22.68 | 2025 | Brukinsa |
| Taiho Oncology, INC. | $20.24 | 2021 | |
| Cti Biopharma Corp. | $19.84 | 2023 | Vonjo |
| Recordati_rare_diseases_inc. | $18.74 | 2025 | Enjaymo |
| Dova Pharmaceuticals | $18.28 | 2021 | |
| Myriad Genetic Laboratories, INC. | $14.61 | 2022 | |
| Morphosys, US INC. | $14.50 | 2023 | Monjuvi |
| Amag Pharmaceuticals, INC. | $13.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Weeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.